Clinical Trials Logo
  1. Home
  2. Carcinoma, Non-Small-Cell Lung
  3. NCT04985357
  4. Details
NCT04985357 Clinical Trial

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT04985357
Other study ID # TRV-002
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date June 2024
Est. completion date May 2030

Study information
Verified date December 2023
Source Travera Inc
Contact Mark Stevens, Ph.D.
Phone 6172999784
Email trv002@travera.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 630
Est. completion date May 2030
Est. primary completion date May 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Sample collection or biopsy of tumor is clinically indicated as part of SOC - Prior to preceding onto therapy for treatment Exclusion Criteria: - Unable to obtain sufficient sample

Study Design

Related Conditions & MeSH terms

  • AML
  • Anus Neoplasms
  • Ascites
  • Breast Neoplasms
  • Carcinoma
  • Carcinoma Breast
  • Carcinoma Cervix
  • Carcinoma of Esophagus
  • Carcinoma of Lung
  • Carcinoma of the Appendix
  • Carcinoma of the Head and Neck
  • Carcinoma of the Oral Cavity
  • Carcinoma of the Oropharynx
  • Carcinoma of the Vulva
  • Carcinoma of Unknown Primary
  • Carcinoma Prostate
  • Carcinoma, Ductal
  • Carcinoma, Hepatocellular
  • Carcinoma, Neuroendocrine
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Ovarian Epithelial
  • Carcinoma, Pancreatic
  • Carcinoma, Renal Cell
  • Carcinoma, Small Cell
  • Carcinoma, Small Cell Lung
  • Carcinoma, Thymic
  • Cholangiocarcinoma
  • Esophageal Neoplasms
  • Lung Neoplasms
  • Malignant Ascites
  • Malignant Pleural Effusion
  • Mesothelioma
  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Pleural Effusion
  • Pleural Effusion, Malignant
  • Prostatic Neoplasms
  • Small Cell Lung Carcinoma
  • Stage III Breast Cancer
  • Stage III Lung Cancer
  • Stage IV Breast Cancer
  • Stage IV Lung Cancer
  • Thymoma
  • Urinary Bladder Neoplasms
  • Vulvar Neoplasms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Travera Inc

Outcome
Type Measure Description Time frame Safety issue
Primary Best overall response (BOR) The best overall response to therapy over 24 months will be captured for correlation with test outcomes. up to 24 months
See also
  Status Clinical Trial Phase
Completed NCT04879849 - A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers Phase 1
Completed NCT04426825 - A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Phase 2
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT02810457 - Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer Phase 3
Completed NCT02864394 - Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) Phase 3
Recruiting NCT04592523 - A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
Recruiting NCT04838548 - A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT04077463 - A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer Phase 1
Recruiting NCT05167604 - Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
Recruiting NCT04603807 - A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases Phase 3
Completed NCT04948411 - Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
Active, not recruiting NCT04487080 - A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Phase 3
Not yet recruiting NCT04255836 - Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT01953913 - Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation Phase 3
Recruiting NCT05715229 - Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy Phase 2
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Suspended NCT05421936 - Osimertinib for NSCLC With Uncommon EGFR Mutations
Completed NCT02847377 - A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC N/A
Completed NCT04427072 - Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Phase 3
Recruiting NCT04823377 - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. N/A

External Links